Sharon B. Wigal

Sharon B. Wigal

Auto-generated profile, based on publicly available information

Sharon B. Wigal

University of California, Child Development Center, 19722 MacArthur Boulevard, Irvine, CA 92612, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2005 in Journal of Attention Disorders
Verified
Journal Article
Closed access
SWSharon B. Wigal
Sharon B. Wigal
JMJames J. McGough
James J. McGough
JMJames T. McCracken
James T. McCracken
JBJoseph Biederman
Joseph Biederman
TSThomas J. Spencer
Thomas J. Spencer
STSimon J. Tulloch
Simon J. Tulloch
Mixed amphetamine salts extended release (MAS XR; Adderall XR®) and atomoxetine (Strattera®) were compared in children 6 to 12 years old with attention deficit/hyperactivity disorder (ADHD) combined or hyperactive/impulsive type in a randomized, double-blind, multicenter, parallel-group, forced-dose-escalation laboratory school study. Primary efficacy measure was the SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) behavioral rating scale. Changes in mean SKAMP deportment scores from baseline were significantly greater for MAS XR ( n = 102) than for atomoxetine ( n = 101) overall (-0.56 and -0.13, respectively; p < .0001) and at each week ( p < .001). Adverse events were similar for both treatment groups. The extended time course of action and greater therapeutic efficacy of MAS XR suggests that it is more effective than atomoxetine in children with ADHD.

9 June 2009 in Child and Adolescent Psychiatry and Mental Health
Verified
Journal Article
Open access
PDF file
SWSharon B Wigal
Sharon B Wigal
SKScott H. Kollins
Scott H. Kollins
ACAnn C Childress
Ann C Childress
LSLiza Squires
Liza Squires
Lisdexamfetamine dimesylate (LDX) is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6 to 12 years of age and in adults. In a previous laboratory school study, LDX demonstrated efficacy 2 hours postdose with duration of efficacy through 12 hours. The current study further characterizes the time course of effect of LDX.

1 November 2004 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PDF file
SWSharon Wigal
Sharon Wigal
JSJames M. Swanson
James M. Swanson
DFDavid Feifel
David Feifel
RSR Bart Sangal
R Bart Sangal
JEJosephine Elia
Josephine Elia
CCC Keith Conners
C Keith Conners

3 August 2012 in Journal of Attention Disorders
Verified
Journal Article
Closed access
SWSharon B. Wigal
Sharon B. Wigal
NENatasha Emmerson
Natasha Emmerson
JGJean-G. Gehricke
Jean-G. Gehricke
PGPietro Galassetti
Pietro Galassetti
ADHD is the most common neurobehavioral disorder of childhood, presenting with pervasive and impairing symptoms of inattention, hyperactivity, impulsivity, or a combination. The leading hypothesis of the underlying physiology of this disorder of inattention and/or hyperactivity-impulsivity is based on catecholamine dysfunction. Pharmacotherapy research indicates that psychostimulants, which are catecholamine agonists, show the greatest efficacy for treating the core symptoms of ADHD. Exercise affects the same dopaminergic and noradrenergic systems that stimulant medications target and is a stressor, which elicits measurable physiological changes. The magnitude of these peripheral alterations is posited as a potential biomarker of ADHD. The hypothesis that exercise training alters the underlying physiology present in ADHD and other medical conditions as well as conceptual issues behind its potential clinical utility is reviewed.

1 August 2006 in Journal of Attention Disorders
Verified
Journal Article
Closed access
SWSharon B. Wigal
Sharon B. Wigal
TWTimothy L. Wigal
Timothy L. Wigal
Objective: ADHD is the most common childhood psychiatric disorder, with impairments seen in home and academic settings. To investigate such impairments in a school-like setting, the laboratory school protocol (LSP) was developed at the University of California, Irvine. Method: This model provides a rigorously controlled environment to examine pharmacodynamic and pharmacokinetic aspects of responses to treatment. A key principle of this methodology is to exercise tight control of the timing and context of measurements by establishing a cycle of activities repeated across each study day. In addition, the LSP approach has been extended to both younger and older populations than the typically studied school-aged group. This extension requires corresponding modifications in measures to characterize drug efficacy and to allow evaluation of ADHD symptoms in a highly standardized setting. Results: This article provides guidelines for employing the LSP for the assessment of medication effects for both preschool and adolescent/adult populations. Conclusion: The LSP can be modified to form either an Adult Workplace Environment or a Preschool Assessment Laboratory.

1 November 2004 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PDF file
DQDeclan Quinn
Declan Quinn
SWSharon Wigal
Sharon Wigal
JSJames Swanson
James Swanson
SHSharon Hirsch
Sharon Hirsch
YOYvonne Ottolini
Yvonne Ottolini
TCThomas Cooper
Thomas Cooper